Innovation

Radical Innovation

One of the highlights of the year on the radical innovation front was the partnership signed by Aché with MSRD (McQuade Center for Strategic Research and Development), a research subsidiary of the Japanese pharmaceutical industry Otsuka. The collaboration between the two companies seeks to advance the development of compound ACH-000029, intended for the treatment of GAD (generalized anxiety) and PTSD (post-traumatic stress) disorders.

The initial research and development phase of the project took about 10 years and involved scientists from Aché and partner companies, contemplating the stages of design, synthesis and biological testing of dozens of molecules to reach the candidate selected by Aché.

The Phase I clinical studies, as well as the production of the formulations to be used in these studies that will be carried out in the next two and a half years, will be carried out in countries with high regulatory rigor.

We have also advanced in the project that will result in the registration and launch of a product indicated for the treatment of vitiligo, with the potential to revolutionize the market, since there is still no treatment available for the disease.

Another relevant initiative carried out by Aché, in the last year, was the expansion of the scope of the Molecular Design and Synthesis Laboratory, focusing on the development of herbal drugs and drugs from Brazilian biodiversity, with the objective of also executing projects from the Bioprospera platform.

Currently, Aché has 13 radical innovation projects under development, eight of them coming from biodiversity and with the first launch scheduled for 2026.

Looking to the future, in 2021, we became part of the Emerge Amazonia program, which aims to leverage the market for science-based technologies that use Amazonian inputs, together with companies from different segments. For 2022, Aché will start another process of prospecting for new drug research projects from national biomes, focusing on therapeutic areas of interest.

 

We maintain the unprecedented partnership with Phytobios and CNPEM (National Center for Research in Energy and Materials) to identify bioactive substances in plant extracts of Brazilian biodiversity, enhancing, in this partnership, the expertise of CNPEM in the development and conduct of tests for the identification of bioactive compounds, using high-tech equipment, Phytobios, which has experience in conducting bioprospecting expeditions in Brazilian biomes and Aché, with its expertise in research and development of innovative drugs, focused o biodiversity.

In addition, we maintain a partnership with public and private universities, in addition to project support notices. Currently, we collaborate with research groups at Unicamp (State University of Campinas), LNBio (National Biosciences Laboratory), USP (University of São Paulo) and UFRJ (Federal University of Rio de Janeiro), focusing on areas such as biodiversity, dermatology and oncology, in addition to encouraging projects from different sectors of civil society.

 

SUPPORT

  • FOLLOW US!

X
  • ATUALIZAÇÃO DA POLÍTICA DE PRIVACIDADE

O Aché Laboratórios Farmacêuticos S.A se preocupa com a sua privacidade e quer que você esteja familiarizado com a forma como coletamos, utilizamos e divulgamos suas informações.

COLETA DE INFORMAÇÕES:

Alguns dados pessoais podem ser solicitados para que você se beneficie de nossos serviços ou programas. Sempre que obrigatório por Lei, seu consentimento será solicitado. Você também poderá exercer seus direitos em relação a seus dados por meio do nosso Canal de Comunicação.

SECURITY:

Empregamos os melhores esforços para respeitar e proteger seus dados pessoais contra perda, roubo, vazamento ou qualquer modalidade de uso indevido, bem como contra acesso não autorizado, divulgação, alteração e destruição.

CANAL DE COMUNICAÇÃO:

Para assuntos exclusivamente relacionados à privacidade de dados, clique aqui.

Para outros assuntos, clique aqui.

Política de privacidade, clique aqui.